ArticleBMC pulmonary medicine2022
Interstitial lung disease in Primary Sjögren's syndrome.
Article in BMC pulmonary medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- ERS/EULAR clinical practice guidelines for connective tissue disease-associated interstitial lung disease.The European respiratory journal · 2026Guideline
- Integration of clinical variables and CT radiomics features in a nomogram for predicting interstitial lung disease in Sjögren's syndrome.Journal of thoracic disease · 2026Article
- Primary Sjögren's syndrome complicated by pleuritis and pleural effusion: a case report and review of the literature.Annals of medicine and surgery (2012) · 2026Article
- Expression characteristics of C-reactive protein in autoimmune diseases and their complications.Frontiers in immunology · 2026Article
- Interleukin-6 as a Biomarker for Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Retrospective Study.International journal of general medicine · 2026Article
- Chronic rhinosinusitis is a risk factor for interstitial lung disease in Sjogren's syndrome.BMC pulmonary medicine · 2025Article
- The Role of Anti-SSB/La Antibodies as Predictors of Decreased Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO) in Primary Sjögren Disease.International journal of molecular sciences · 2025Article
- Long-term outcome of interstitial lung disease in patients with primary Sjögren's syndrome: a retrospective observational study.The Korean journal of internal medicine · 2025Observational
- Prevalence of Interstitial Lung Disease in Patients with Primary Sjogren's Syndrome: A Systematic Review and Meta-analysis of Observational Studies : Prevalence of Interstitial Lung Disease in Patients with Primary Sjogren's Syndrome.Galen medical journal · 2025Review
- A Practical Multidisciplinary Approach to Identifying Interstitial Lung Disease in Systemic Autoimmune Rheumatic Diseases: A Clinician's Narrative Review.Diagnostics (Basel, Switzerland) · 2024Review
- Article
- Interstitial Lung Disease in Primary Sjögren's Syndrome: Risk factors for occurrence and radiographic progression.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2024Article
- Long-term functional course of Sjögren's disease-associated interstitial lung disease.ERJ open research · 2024Article
- Interstitial lung disease and associated factors in patients with Sjögren's syndrome.Irish journal of medical science · 2024Article
- Clinical features and risk factors of primary Sjögren's syndrome complicated with severe pneumonia: a case-control study.Clinical rheumatology · 2024Article
- Pulmonary Involvement in Sjögren's Syndrome: Correlations with Biomarkers of Activity and High-Resolution Computer Tomography Findings.Journal of clinical medicine · 2024Article
- Respiratory infection risk in primary Sjögren's syndrome complicated with interstitial lung disease: a retrospective study.Clinical rheumatology · 2024Article
- Use of pirfenidone in fibrotic interstitial lung diseases and beyond: a review.Frontiers in medicine · 2024Review
- The analysis of the pulmonary domain involvement in Sjögren's disease.Therapeutic advances in musculoskeletal disease · 2024Article
- Are there differences in the clinical and laboratory features of patients with seronegative primary Sjögren's syndrome?Turkish journal of medical sciences · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundInterstitial lung disease (ILD) may cause life-threatening complications of primary Sjogren's syndrome (pSS), and has a poor prognosis in terms of survival and quality of life. To date, few studies have investigated the risk factors for ILD detected by high-resolution computed tomography (HRCT) in pSS patients with or without respiratory symptoms.
methodsData of 333 patients with newly diagnosed pSS were retrospectively analysed. Interstitial lung disease involvement was defined as typical abnormalities on HRCT and/or pulmonary function tests. Multivariate regression model was used to evaluate the association between interstitial lung disease and pSS characteristics.
resultsSixty-six patients (19.82%) were diagnosed with pSS-ILD. Ground glass opacities (87.88%) and septal/sub pleural lines (81.82%) were most frequent. Based on pulmonary high-resolution computed tomography, patients were divided into nonspecific (n = 42), usual (n = 20), lymphocytic interstitial pneumonia (n = 3) and cryptogenic organising pneumonia (n = 1) groups. There was a strong association between erythrocyte sedimentation rate (ESR)/C-reactive protein (CRP) and the HRCT-score. Pulmonary function tests revealed impaired diffusion capacity for carbon monoxide and total lung capacity, and coexistence of small airway lesions in pSS-interstitial lung disease. On logistic regression analysis, age, Raynaud's phenomenon, lymphopenia, cough, dyspnoea and rampant dental caries were risk factors associated with pSS-interstitial lung disease.
conclusionsInterstitial lung disease involvement in pSS is a common clinical occurrence. The clinical manifestation is nonspecific and variable; Raynaud's phenomenon and lymphopenia may predict its onset. pSS patients with advanced age, dry cough and dyspnoea should be systematically evaluated for ILD involvement and managed according to their symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.